Literature DB >> 19259288

Irinotecan-induced dysarthria: an insight into its pathogenesis?

Jesus A Gomez1, Ines Sanchez, Jose A Ramirez.   

Abstract

Entities:  

Year:  2008        PMID： 19259288      PMCID： PMC2632824     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  14 in total

1.  Irinotecan-induced central nervous system toxicity: a case report.

Authors:  I Sevilla Garcia; A Rueda; E Alba
Journal:  J Natl Cancer Inst       Date:  1999-04-07       Impact factor: 13.506

2.  [Dysarthria during irinotecan administration].

Authors:  B Ceccaldi; F Kara; H Mommeja-Marin; M Bègue; P Saint Blancard; E Le Marec; D Hauteville
Journal:  Rev Med Interne       Date:  2002-11       Impact factor: 0.728

3.  Irinotecan chemotherapy associated with transient dysarthria and aphasia.

Authors:  S De Marco; E Squilloni; L Vigna; M F Bertagnolio; C N Sternberg
Journal:  Ann Oncol       Date:  2004-07       Impact factor: 32.976

4.  Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.

Authors:  S M Blaney; C Takimoto; D J Murry; N Kuttesch; C McCully; D E Cole; K Godwin; F M Balis
Journal:  Cancer Chemother Pharmacol       Date:  1998       Impact factor: 3.333

5.  Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.

Authors:  J Valencak; M Raderer; G V Kornek; M H Henja; W Scheithauer
Journal:  J Natl Cancer Inst       Date:  1998-01-21       Impact factor: 13.506

6.  Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan.

Authors:  C Blandizzi; B De Paolis ; R Colucci; G Lazzeri; F Baschiera; M Del Tacca
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 7.  DNA topoisomerases: essential enzymes and lethal targets.

Authors:  A Y Chen; L F Liu
Journal:  Annu Rev Pharmacol Toxicol       Date:  1994       Impact factor: 13.820

8.  Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.

Authors:  Anupama Goel; Michael L Grossbard; Stephen Malamud; Peter Homel; Margaret Dietrich; Teresa Rodriguez; Takhir Mirzoyev; Peter Kozuch
Journal:  Anticancer Drugs       Date:  2007-03       Impact factor: 2.248

Review 9.  Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective.

Authors:  H Bleiberg; E Cvitkovic
Journal:  Eur J Cancer       Date:  1996       Impact factor: 9.162

10.  Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.

Authors:  F Saliba; R Hagipantelli; J L Misset; G Bastian; G Vassal; M Bonnay; P Herait; C Cote; M Mahjoubi; D Mignard; E Cvitkovic
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544
View more
  3 in total

1.  FOLFIRINOX-induced reversible dysarthria: A case report and review of previous cases.

Authors:  Ayumu Matsuoka; Osamu Maeda; Megumi Inada-Inoue; Eizaburo Ohno; Yoshiki Hirooka; Yukihiro Yokoyama; Tsutomu Fujii; Masato Nagino; Hidemi Goto; Yuichi Ando
Journal:  Oncol Lett       Date:  2015-08-11       Impact factor: 2.967

2.  Irinotecan-induced dysarthria.

Authors:  Albertine J Dressel; Johannes C van der Mijn; Ijke J Aalders; Rico N P M Rinkel; Hans J van der Vliet
Journal:  Case Rep Oncol       Date:  2012-01-18

3.  Irinotecan-Associated Dysarthria in Patients with Pancreatic Cancer: A Single Site Experience.

Authors:  Ali Elbeddini; Naushin Hooda; Mohamed Gazarin; Penny Webster; Jackie McMillan
Journal:  Am J Case Rep       Date:  2020-06-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.